NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Universal Display Corporation ("Universal Display Corporation") (NASDAQ:OLED) concerning possible violations of federal securities laws. On August 1, 2024, Universal reported solid 2Q 2024 results and raised the bottom-end of its full […]

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CECO Environmental Corp. ("CECO Environmental Corp.") (NASDAQ:CECO) concerning possible violations of federal securities laws. CECO issued a press release on January 16, 2025, "announc[ing] preliminary financial results for the fourth quarter and

(NASDAQ:XFOR), Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. 24, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune

(Neo:ABXX.NE),(OTC US:ABXXF),(Other OTC:ABXXF),(Neo:ABXX), /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Jan. 24, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE CA:ABXX) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte. Ltd., the owner of Abaxx Commodity Exchange and

(ASX – Trade24:ATH.AX),(NASDAQ:ATHE), Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025 ATH434-201 trial in early-stage MSA completed in November 2024 Positive interim data presented at MDS from the ATH434-202 Phase 2 trial in advanced MSA Multiple data presentations and publications showing the potential

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:ATRA) concerning possible violations of federal securities laws. Atara issued a press release on January 16, 2025, announcing receipt of "a Complete Response Letter (CRL) from

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Capri Holdings Limited (NYSE:CPRI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/capri-holdings-lawsuit-submission-form?prid=124848&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Rentokil Initial plc (NYSE:RTO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rentokil-initial-plc-lawsuit-submission-form?prid=124845&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=124842&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Aehr Test Systems, Inc. (NASDAQ:AEHR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/aehr-lawsuit-submission-form?prid=124825&wire=1 or contact Joseph E. Levi, Esq. via email at